Protagenic Therapeutics, Inc.\new (PTIX) Form 8-K — Nov 17, 2026
Protagenic Therapeutics closed the initial tranche of a private placement on November 17, 2026, raising approximately $1.5 million gross at $0.61 per share — a price set at 90% of the trailing 30-day VWAP. Each share came with Series A warrants ($0.67 exercise) and Series B warrants ($0.73 exercise), each covering 100% of the shares purchased, so potential dilution roughly triples the headline share count if all warrants are exercised. The offering can run to $3 million (expandable to $5 million) through December 31, 2026, with Brookline Capital Markets earning a 7% cash fee, 1% expense allowance, and 7% warrant coverage.
Key figures
- Gross Proceeds
- 1500000
- Offering Price
- 0.61
- Shares Offered
- 2459014
- Price vs vwap
- 90% of 30-day VWAP
- Warrant expiry
- 5 years, or earlier on 200% VWAP trigger or 10th GAD patient dosed
- Maximum offering amount
- $3,000,000 (may increase to $5,000,000)
- Placement agent fee pct
- 7
- Placement agent expense cap
- 75000
- Series a warrant exercise price
- 0.67
- Series b warrant exercise price
- 0.73
- Non accountable expense allowance pct
- 1
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.